[go: up one dir, main page]

BG106249A - Composition of a-beta peptide and process for producing same - Google Patents

Composition of a-beta peptide and process for producing same

Info

Publication number
BG106249A
BG106249A BG106249A BG10624901A BG106249A BG 106249 A BG106249 A BG 106249A BG 106249 A BG106249 A BG 106249A BG 10624901 A BG10624901 A BG 10624901A BG 106249 A BG106249 A BG 106249A
Authority
BG
Bulgaria
Prior art keywords
composition
producing same
beta peptide
compositions
abeta peptide
Prior art date
Application number
BG106249A
Other languages
Bulgarian (bg)
Inventor
Pamela Hirtzer
Naina Patel
Original Assignee
Neuralab, Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab, Ltd filed Critical Neuralab, Ltd
Publication of BG106249A publication Critical patent/BG106249A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention is directed to compositions comprising solubilized Abeta peptide or suspension of Abeta peptide and to processes for producing the same by adjusting the pH sufficient to effect the solubilization, and sterile filtration thereof, to methods of treating and preventing Alzheimer's disease with the obtained compositions. 47 claims, 2 figures
BG106249A 1999-06-01 2001-12-20 Composition of a-beta peptide and process for producing same BG106249A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13704799P 1999-06-01 1999-06-01
PCT/US2000/015302 WO2000072870A1 (en) 1999-06-01 2000-06-01 Compositions of a-beta peptide and processes for producing same

Publications (1)

Publication Number Publication Date
BG106249A true BG106249A (en) 2002-08-30

Family

ID=22475602

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106249A BG106249A (en) 1999-06-01 2001-12-20 Composition of a-beta peptide and process for producing same

Country Status (25)

Country Link
EP (1) EP1181040A1 (en)
JP (1) JP2003519620A (en)
KR (1) KR20020016813A (en)
CN (1) CN1353615A (en)
AR (1) AR024558A1 (en)
AU (1) AU5726100A (en)
BG (1) BG106249A (en)
BR (1) BR0011251A (en)
CA (1) CA2374897A1 (en)
CZ (1) CZ20014150A3 (en)
EE (1) EE200100649A (en)
HK (1) HK1045938A1 (en)
HR (1) HRP20010901A2 (en)
IL (1) IL146575A0 (en)
IS (1) IS6182A (en)
MX (1) MXPA01012355A (en)
NO (1) NO20015859L (en)
NZ (1) NZ515744A (en)
PE (1) PE20010212A1 (en)
PL (1) PL352575A1 (en)
RU (1) RU2001135800A (en)
SK (1) SK17012001A3 (en)
TR (1) TR200103476T2 (en)
WO (1) WO2000072870A1 (en)
ZA (1) ZA200109704B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP2082749A3 (en) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Prevention and treatment of Alzheimer's disease
AU1225702A (en) * 2000-09-19 2002-04-02 Evotec Neurosciences Gmbh Methods and compounds for treating brain amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
CN117903302A (en) 2005-11-30 2024-04-19 Abbvie 公司 Anti-aβ globulomer antibodies, related products thereof, methods of producing said antibodies, uses of said antibodies, and methods of use
ES2453941T5 (en) 2005-11-30 2017-05-31 Abbvie Inc. Monoclonal antibodies against beta amyloid protein and uses thereof
AU2007227813B2 (en) 2006-03-23 2012-09-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (en) 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN104744591B (en) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 Amyloid beta binding proteins
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
IL282823B2 (en) 2014-07-10 2024-05-01 Eisai Res And Development Management Co Ltd Antibodies that bind to A beta protofibrils and uses thereof
PL3400019T3 (en) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
IL259659B (en) 2016-01-08 2022-08-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
CN114957438B (en) * 2022-06-28 2024-04-02 福建亿彤生物科技有限公司 Human Aβ1-42 antigenic determinant polypeptide for detecting Alzheimer's disease and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016819A1 (en) * 1990-04-27 1991-11-14 Molecular Rx., Inc. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
EP1181040A1 (en) 2002-02-27
KR20020016813A (en) 2002-03-06
BR0011251A (en) 2002-03-05
TR200103476T2 (en) 2002-04-22
MXPA01012355A (en) 2003-06-24
NO20015859D0 (en) 2001-11-30
PL352575A1 (en) 2003-08-25
IL146575A0 (en) 2002-07-25
AU5726100A (en) 2000-12-18
WO2000072870A1 (en) 2000-12-07
HRP20010901A2 (en) 2003-04-30
CN1353615A (en) 2002-06-12
IS6182A (en) 2001-11-29
EE200100649A (en) 2003-02-17
AR024558A1 (en) 2002-10-16
RU2001135800A (en) 2003-08-20
SK17012001A3 (en) 2002-06-04
ZA200109704B (en) 2003-02-26
HK1045938A1 (en) 2002-12-20
NZ515744A (en) 2004-04-30
CZ20014150A3 (en) 2002-05-15
PE20010212A1 (en) 2001-02-22
CA2374897A1 (en) 2000-12-07
NO20015859L (en) 2002-02-01
JP2003519620A (en) 2003-06-24

Similar Documents

Publication Publication Date Title
BG106249A (en) Composition of a-beta peptide and process for producing same
BG66103B1 (en) Condensed pyrrolocarbazoles
BG66083B1 (en) Pharmaceutical compositions containing antibodies, and antibodies for prevention andf treatment of amyloidogenic disease
WO2002002506A3 (en) Compounds to treat alzheimer's disease
WO2002002512A3 (en) Compounds to treat alzheimer's disease
ES2114471A1 (en) Process for preparation of paroxetin hydrochloride anhydrate
AU2001252958A1 (en) Compounds and methods to treat alzheimer's disease
DE69111642D1 (en) Gabapentin and its derivatives for the treatment of neurodegenerative diseases.
DE60016461D1 (en) METHOD FOR TREATING GLASSES AND GLASSES FOR PREPARING DISPLAY TOUCHS
IL189629A0 (en) Compositions containing human ctla-4 antibodies
IL193814A0 (en) 1 -acetyl- 3,3 dimethyl- 6- amino- 2, 3 - dihydroindole and process for producing same
MXPA04005376A (en) Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses.
ATE430193T1 (en) RECOMBINANT ALPHA-L-IDURONIDASE AND TREATMENT OF DEFICIENCY DISEASES CAUSED BY IT
TW200502221A (en) Novel lactams and uses thereof
MXPA04000338A (en) Diaminediols for the treatment of alzheimer's disease.
AU1618000A (en) Use of radioligands to screen inhibitors of amyloid-beta peptide production
ATE401072T1 (en) 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USABLE FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM
MXPA03011521A (en) Aminediols as agents for the treatment of alzheimer's disease.
RS8504A (en) Novel cyclohexil sulphones
IL141325A0 (en) Tan-1057 derivatives
DE69805305D1 (en) USE OF PHANQUINON FOR THE TREATMENT OF ALZHEIMER'S DISEASE
BG102707A (en) New triazolopurinpurines, method for their preparation and appplication as medicamentous forms
TW200504036A (en) Novel lactams and uses thereof
MXPA04000337A (en) Aminediols for the treatment of alzheimer's disease.
EP1446400A4 (en) Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same